Core Viewpoint - The listing of the RAIN token on the Kraken cryptocurrency exchange is expected to enhance liquidity and accessibility for participants in the RAIN ecosystem, contributing to improved price discovery and secondary market trading [1][3]. Group 1: Company Overview - Enlivex Therapeutics Ltd. is focused on the late-stage clinical development of Allocetra™, a novel therapy for osteoarthritis, and has adopted a treasury strategy centered on the RAIN token [4]. - RAIN serves as the governance and utility token for a decentralized predictions and options protocol built on the Arbitrum network, allowing users to create and trade markets tied to real-world events [3]. Group 2: Market Context - Kraken, the second-largest U.S.-based cryptocurrency exchange, supports a wide range of digital assets and had a total trading volume exceeding $2 trillion in 2025, making it a significant platform for secondary market trading [2]. - The exchange is known for its strong security, regulatory compliance, and transparency, attracting institutional and professional market participants [2]. Group 3: Clinical Development Focus - Osteoarthritis affects over 32.5 million Americans and more than 300 million individuals globally, with projections indicating that 78 million Americans will have the condition by 2040 [5]. - The burden of osteoarthritis is substantial, leading to over one million hospitalizations annually in the U.S., primarily for total joint replacement, highlighting the critical need for effective treatments [5].

Core Viewpoint - Enlivex Therapeutics has successfully listed its primary treasury asset, the RAIN token, on the WhiteBIT cryptocurrency exchange, enhancing market access and liquidity for the token [1][2]. Group 1: Company Overview - Enlivex Therapeutics is a clinical stage company focused on macrophage reprogramming immunotherapy, particularly in the late-stage clinical development of Allocetra™, aimed at treating osteoarthritis [4]. - The company has developed a treasury strategy centered on RAIN, which serves as its primary treasury reserve asset, providing investors with exposure to digital capital [4]. Group 2: RAIN Token and Market Strategy - The RAIN token is the governance and utility token of a decentralized predictions and options protocol on the Arbitrum network, allowing users to create and trade markets tied to real-world events [3]. - The listing of RAIN on WhiteBIT, the largest European cryptocurrency exchange by traffic, is expected to broaden regional market access and enhance secondary market liquidity, supporting the development of market infrastructure for Enlivex's digital asset strategy [2]. Group 3: Osteoarthritis Market Context - Osteoarthritis affects over 32.5 million Americans and more than 300 million individuals globally, with projections indicating that 78 million Americans will have the condition by 2040 [5]. - The burden of osteoarthritis is significant, leading to over one million hospitalizations annually in the U.S., primarily for total joint replacement, highlighting the critical need for effective treatments [5].

Core Viewpoint - Enlivex Therapeutics Ltd. has announced its decision to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange (TASE) to focus on U.S.-based trading and reduce administrative costs associated with dual listing [1][4]. Group 1: Delisting Process - The last trading day for the ordinary shares on the TASE is expected to be April 23, 2026, with delisting anticipated around April 26, 2026 [2]. - Shareholders will continue to trade ordinary shares on the TASE until the final trading day [2]. - The ordinary shares will continue to be traded on the Nasdaq Capital Market under the symbol "ENLV" [3]. Group 2: Strategic Objectives - The Board of Directors approved the delisting to operate under a single set of listing requirements, which aims to reduce duplicative administrative costs and potentially enhance liquidity on Nasdaq [4]. - The transition allows the company to concentrate its investor and public relations efforts on the U.S. capital markets [4]. Group 3: Company Overview - Enlivex is a clinical-stage biotech company focused on macrophage reprogramming immunotherapy, particularly in the late-stage clinical development of Allocetra™, a therapy for osteoarthritis [5]. - Osteoarthritis affects over 32.5 million Americans and is projected to impact 78 million by 2040, highlighting a significant market need for effective treatments [6].